State of Alaska Department of Revenue Has $11.74 Million Holdings in Edwards Lifesciences Corp (NYSE:EW)

State of Alaska Department of Revenue increased its stake in Edwards Lifesciences Corp (NYSE:EW) by 61.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,383 shares of the medical research company’s stock after buying an additional 20,302 shares during the quarter. State of Alaska Department of Revenue’s holdings in Edwards Lifesciences were worth $11,738,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nuveen Asset Management LLC raised its stake in Edwards Lifesciences by 8,278.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock valued at $730,013,000 after acquiring an additional 3,904,405 shares during the period. FMR LLC raised its stake in Edwards Lifesciences by 7.9% in the 1st quarter. FMR LLC now owns 8,175,796 shares of the medical research company’s stock valued at $1,564,274,000 after acquiring an additional 598,976 shares during the period. Bessemer Group Inc. raised its stake in Edwards Lifesciences by 56,300.0% in the 2nd quarter. Bessemer Group Inc. now owns 503,652 shares of the medical research company’s stock valued at $93,045,000 after acquiring an additional 502,759 shares during the period. Marshall Wace North America L.P. raised its stake in Edwards Lifesciences by 394.9% in the 2nd quarter. Marshall Wace North America L.P. now owns 364,492 shares of the medical research company’s stock valued at $67,336,000 after acquiring an additional 290,838 shares during the period. Finally, Jennison Associates LLC raised its stake in Edwards Lifesciences by 4.8% in the 2nd quarter. Jennison Associates LLC now owns 6,039,006 shares of the medical research company’s stock valued at $1,115,646,000 after acquiring an additional 275,182 shares during the period. 81.53% of the stock is owned by institutional investors.

EW stock traded up $6.40 during trading hours on Friday, hitting $229.40. 1,370,371 shares of the stock were exchanged, compared to its average volume of 1,248,235. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $47.71 billion, a P/E ratio of 48.81, a P/E/G ratio of 2.71 and a beta of 0.84. The company has a 50-day simple moving average of $219.14 and a two-hundred day simple moving average of $196.00. Edwards Lifesciences Corp has a 12 month low of $136.44 and a 12 month high of $229.97.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, topping the Zacks’ consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the business earned $1.24 earnings per share. Edwards Lifesciences’s revenue was up 15.2% on a year-over-year basis. On average, equities research analysts predict that Edwards Lifesciences Corp will post 5.34 earnings per share for the current year.

In related news, VP Huimin Wang sold 4,650 shares of the firm’s stock in a transaction on Friday, October 4th. The stock was sold at an average price of $223.18, for a total value of $1,037,787.00. Following the transaction, the vice president now owns 36,898 shares in the company, valued at $8,234,895.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael A. Mussallem sold 22,850 shares of the firm’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $189.14, for a total value of $4,321,849.00. Following the completion of the transaction, the chief executive officer now owns 105,770 shares in the company, valued at approximately $20,005,337.80. The disclosure for this sale can be found here. Insiders sold 184,041 shares of company stock worth $38,984,226 in the last 90 days. 1.63% of the stock is owned by company insiders.

A number of research firms recently weighed in on EW. Raymond James increased their price target on Edwards Lifesciences from $200.00 to $232.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 price target on the stock in a research note on Thursday, July 25th. Wells Fargo & Co increased their price target on Edwards Lifesciences from $220.00 to $250.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. BMO Capital Markets increased their price target on Edwards Lifesciences from $204.00 to $224.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, BTIG Research restated a “hold” rating on shares of Edwards Lifesciences in a research note on Thursday, July 25th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Edwards Lifesciences has a consensus rating of “Buy” and a consensus target price of $208.42.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: How are the companies in the S&P 500 selected?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.